{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:12:09Z","timestamp":1787163129032,"version":"build-2736575974"},"reference-count":271,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T00:00:00Z","timestamp":1633305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Fondazione CRT project 2019","award":["2252"],"award-info":[{"award-number":["2252"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Cutaneous melanoma is one of the most aggressive solid tumors, with a low survival for the metastatic stage. Currently, clinical melanoma treatments include surgery, chemotherapy, targeted therapy, immunotherapy and radiotherapy. Of note, innovative therapeutic regimens concern the administration of multitarget drugs in tandem, in order to improve therapeutic efficacy. However, also, if this drug combination is clinically relevant, the patient\u2019s response is not yet optimal. In this scenario, nanotechnology-based delivery systems can play a crucial role in the clinical treatment of advanced melanoma. In fact, their nano-features enable targeted drug delivery at a cellular level by overcoming biological barriers. Various nanomedicines have been proposed for the treatment of cutaneous melanoma, and a relevant number of them are undergoing clinical trials. In Italy, researchers are focusing on the pharmaceutical development of nanoformulations for malignant melanoma therapy. The present review reports an overview of the main melanoma-addressed nanomedicines currently under study in Italy, alongside the state of the art of melanoma therapy. Moreover, the latest Italian advances concerning the pre-clinical evaluation of nanomedicines for melanoma are described.<\/jats:p>","DOI":"10.3390\/pharmaceutics13101617","type":"journal-article","created":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T21:26:20Z","timestamp":1633728380000},"page":"1617","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Nanotechnology Addressing Cutaneous Melanoma: The Italian Landscape"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5081-3638","authenticated-orcid":false,"given":"Luigi","family":"Battaglia","sequence":"first","affiliation":[{"name":". Department of Drug Science and Technology, University of Torino, 10125 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4751-620X","authenticated-orcid":false,"given":"Anna","family":"Scomparin","sequence":"additional","affiliation":[{"name":". Department of Drug Science and Technology, University of Torino, 10125 Turin, Italy"},{"name":". Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2246-3183","authenticated-orcid":false,"given":"Chiara","family":"Dianzani","sequence":"additional","affiliation":[{"name":". Department of Drug Science and Technology, University of Torino, 10125 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4245-4161","authenticated-orcid":false,"given":"Paola","family":"Milla","sequence":"additional","affiliation":[{"name":". Department of Drug Science and Technology, University of Torino, 10125 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9739-6667","authenticated-orcid":false,"given":"Elisabetta","family":"Muntoni","sequence":"additional","affiliation":[{"name":". Department of Drug Science and Technology, University of Torino, 10125 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Arpicco","sequence":"additional","affiliation":[{"name":". Department of Drug Science and Technology, University of Torino, 10125 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Cavalli","sequence":"additional","affiliation":[{"name":". Department of Drug Science and Technology, University of Torino, 10125 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejca.2021.04.029","article-title":"Epidemiology of cutaneous melanoma and keratinocyte cancer in white populations 1943\u20132036","volume":"152","author":"Garbe","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s40257-019-00456-4","article-title":"Adjuvant Treatment of Melanoma: Recent Developments and Future Perspectives","volume":"20","author":"Testori","year":"2019","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_4","unstructured":"American Cancer Society (2018). Cancer Facts & Figures 2018, American Cancer Society."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"500","DOI":"10.4065\/81.4.500","article-title":"Cutaneous malignant melanoma","volume":"81","author":"Cummins","year":"2006","journal-title":"Mayo Clin. Proc."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.suc.2019.09.004","article-title":"Pathology of Melanoma","volume":"100","author":"Chopra","year":"2020","journal-title":"Surg. Clin. NA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3389\/fnmol.2019.00111","article-title":"Stem cell-derived models of neural crest are essential to understand melanoma progression and therapy resistance","volume":"12","author":"Utikal","year":"2019","journal-title":"Front. Mol. Neurosci."},{"key":"ref_8","first-page":"705","article-title":"The histogenesis and biologic behavior of primary human malignant melanomas of the skin","volume":"29","author":"Clark","year":"1969","journal-title":"Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/archderm.1980.01640310043015","article-title":"Acral lentiginous melanoma","volume":"116","author":"Coleman","year":"1980","journal-title":"Arch. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/0190-9622(95)90282-1","article-title":"Lentigo maligna and lentigo maligna melanoma","volume":"33","author":"Cohen","year":"1995","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.hoc.2009.03.013","article-title":"The classification of cutaneous melanoma","volume":"23","author":"Duncan","year":"2009","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_12","first-page":"315","article-title":"Histological type and biological behavior of primary cutaneous malignant melanoma. 1. An analysis of 1916 cases","volume":"401","year":"1983","journal-title":"Virchows Arch. A Pathol. Anat. Histopathol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jaad.2011.05.030","article-title":"Melanoma survival in the United States, 1992 to 2005","volume":"65","author":"Pollack","year":"2011","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/CMR.0000000000000245","article-title":"Superficial spreading melanoma: An analysis of 97.702 cases using the SEER database","volume":"26","author":"Singh","year":"2016","journal-title":"Melanoma Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/oxfordjournals.aje.a112400","article-title":"Mathematical models of age and ultraviolet effects on the incidence of skin cancer among whites in the United States","volume":"105","author":"Fears","year":"1977","journal-title":"Am. J. Epidemiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"460","DOI":"10.2340\/00015555-2855","article-title":"Nodular melanoma: A histopathologic entity?","volume":"98","author":"Green","year":"2018","journal-title":"Acta Derm. Venereol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/archdermatol.2008.609","article-title":"Acral lentiginous melanoma: Incidence and survival patterns in the United States, 1986\u20132005","volume":"145","author":"Bradford","year":"2009","journal-title":"Arch Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.path.2009.08.005","article-title":"Acral lentiginous melanoma","volume":"2","author":"Piliang","year":"2009","journal-title":"Surg. Pathol. Clin."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/bjd.15600","article-title":"Prognostic factors and survival in acral lentiginous melanoma","volume":"177","author":"Asgari","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/S0140-6736(18)31071-7","article-title":"Acral lentiginous melanoma","volume":"391","author":"Liu","year":"2018","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3109\/00313028509063771","article-title":"Malignant melanoma in situ: The flat, curable stage of malignant melanoma","volume":"17","author":"Ackerman","year":"1985","journal-title":"Pathology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0046-8177(84)80310-X","article-title":"A study of tumor progression: The precursor lesions of superficial spreading and nodular melanoma","volume":"15","author":"Clark","year":"1984","journal-title":"Hum. Pathol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.pathol.2015.12.002","article-title":"Melanoma progression","volume":"48","author":"Elder","year":"2016","journal-title":"Pathology"},{"key":"ref_24","unstructured":"Amin, M.B., Edge, S.B., Greene, F.L., Carducci, M.A., and Compton, C.A. (2017). Melanoma of the skin. AJCC Cancer Staging Manual, Springer International Publishing. [8th ed.]."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1146\/annurev-pathol-012513-104658","article-title":"The molecular pathology of melanoma: An integrated taxonomy of melanocytic neoplasia","volume":"9","author":"Bastian","year":"2014","journal-title":"Annu. Rev. Pathol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.soncn.2013.06.002","article-title":"Skin cancer: An overview of epidemiology and risk factors","volume":"29","author":"Gordon","year":"2013","journal-title":"Semin. Oncol. Nurs."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Scolyer, R.A., Rawson, R.V., Gershenwald, J.E., Ferguson, P.M., and Prieto, V.G. (2020). Melanoma pathology reporting and staging. Mod. Pathol., 15\u201324.","DOI":"10.1038\/s41379-019-0402-x"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3390\/cancers3010126","article-title":"Decoding melanoma metastasis","volume":"3","author":"Damsky","year":"2011","journal-title":"Cancers"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"460","DOI":"10.3322\/caac.21352","article-title":"State of the science on prevention and screening to reduce melanoma incidence and mortality: The time is now","volume":"66","author":"Tripp","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/j.1755-148X.2011.00880.x","article-title":"The melanomas: A synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin","volume":"24","author":"Whiteman","year":"2011","journal-title":"Cell Melanoma Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1007\/s11912-013-0342-4","article-title":"Sun exposure, sunbeds and sunscreens and melanoma. What are the controversies?","volume":"15","author":"Bataille","year":"2013","journal-title":"Curr. Oncol. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrc.2016.37","article-title":"From melanocytes to melanomas","volume":"16","author":"Shain","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/exd.12363","article-title":"How, and from which cell sources, do nevi really develop?","volume":"23","author":"Grichnik","year":"2014","journal-title":"Exp. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"12222","DOI":"10.3390\/ijms140612222","article-title":"UV radiation and the skin","volume":"14","author":"Jarrett","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/S0140-6736(04)15649-3","article-title":"Is there more than one road to melanoma?","volume":"363","author":"Rivers","year":"2004","journal-title":"Lancet"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jphotobiol.2018.06.005","article-title":"Ultraviolet radiation-mediated development of cutaneous melanoma: An update","volume":"185","author":"Emri","year":"2018","journal-title":"J. Photochem. Photobiol. B"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1093\/jnci\/djg123","article-title":"Determinants of BRAF mutations in primary melanoma","volume":"95","author":"Maldonado","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMoa050092","article-title":"Distinct sets of genetic alterations in melanoma","volume":"353","author":"Curtin","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/sj.jid.5701028","article-title":"Epidemiologic Support for Melanoma Heterogeneity Using the Surveillance, Epidemiology, and End Results Program","volume":"128","author":"Lachiewicz","year":"2008","journal-title":"J. Invest. Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1001\/archderm.139.5.667","article-title":"Hypothesis: A role for telomere crisis in spontaneous regression of melanoma","volume":"139","author":"Bastian","year":"2003","journal-title":"Arch. Dermatol."},{"key":"ref_41","first-page":"1005","article-title":"Melanoma: Epidemiology, risk factors, pathogenesis, diagnosis and classification","volume":"28","author":"Rastrelli","year":"2014","journal-title":"In Vivo"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1016\/j.ejca.2009.05.009","article-title":"Meta-analysis of risk factors for cutaneous melanoma according to anatomical site and clinico-pathological variant","volume":"45","author":"Caini","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_43","unstructured":"Porter, R.S. (2011). The Merck Manual of Diagnosis and Therapy, Merck Sharpe & Dohme Corp.. [19th ed.]."},{"key":"ref_44","first-page":"232","article-title":"Skin cancer education in transplant recipients","volume":"18","author":"Feuerstein","year":"2008","journal-title":"Transplantation"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1365-2133.2008.08837.x","article-title":"Skin cancer surveillance in renal transplant recipients: Re-evaluation of U.K. practice and comparison with Australian experience","volume":"160","author":"Garg","year":"2009","journal-title":"Br. J. Dermatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa1502583","article-title":"The genetic evolution of melanoma from precursor lesions","volume":"373","author":"Shain","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1002\/cncr.31345","article-title":"Melanoma: What do all the mutations mean?","volume":"124","author":"Davis","year":"2018","journal-title":"Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1038\/ng.2359","article-title":"Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma","volume":"44","author":"Krauthammer","year":"2012","journal-title":"Nat. Genet."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/nature11624","article-title":"An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair\/ fair skin background","volume":"491","author":"Mitra","year":"2012","journal-title":"Nature"},{"key":"ref_51","unstructured":"Cancer Genome Atlas Network (2015). Genomic classification of cutaneous melanoma. Cell, 161, 1681\u20131696."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1158\/0008-5472.CAN-04-2423","article-title":"Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors","volume":"65","author":"Sharma","year":"2005","journal-title":"Cancer Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","article-title":"Prognostic and clinico-pathologic associations of oncogenic BRAF in metastatic melanoma","volume":"29","author":"Long","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Lovly, C.M., Dahlman, K.B., Fohn, L.E., Su, Z., Dias-Santagata, D., Hicks, D.J., Hucks, D., Berry, E., Terry, C., and Duke, M. (2012). Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0035309"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1158\/1078-0432.CCR-12-0052","article-title":"Distinguishing clinico-pathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma","volume":"18","author":"Menzies","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.suc.2019.09.013","article-title":"Principles of Targeted Therapy for Melanoma","volume":"100","author":"Sun","year":"2020","journal-title":"Surg. Clin. N. Am."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.sder.2010.10.005","article-title":"Epidemiology of melanoma","volume":"29","author":"Rigel","year":"2010","journal-title":"Semin. Cutan. Med. Surg."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Simpson, C.M., Ferrari, N., Calvo, F., and Bakal, C. (2018). The dynamics of ERK signaling in melanoma, and the response to BRAF or MEK inhibition, are cell cycle dependent. bioRxiv, 306571.","DOI":"10.1101\/306571"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/ijc.10978","article-title":"A pivotal role for ERK in the oncogenic behaviour of malignant melanoma?","volume":"104","author":"Smalley","year":"2003","journal-title":"Int. J. Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Hodorogea, A., Calinescu, A., Antohe, M., Balaban, M., Nedelcu, R.I., Turcu, G., Ion, D.A., Badarau, I.A., Popescu, C.M., and Popescu, R. (2019). Epithelial-Mesenchymal Transition in Skin Cancers: A Review. Anal. Cell Pathol., 3851576.","DOI":"10.1155\/2019\/3851576"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Tang, Y., Durand, S., Dalle, S., and Caramel, J. (2020). EMT-Inducing Transcription Factors, Drivers of Melanoma Phenotype Switching, and Resistance to Treatment. Cancers, 12.","DOI":"10.3390\/cancers12082154"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"6449","DOI":"10.21873\/anticanres.11243","article-title":"Epithelial-Mesenchymal Expression Phenotype of Primary Melanoma and Matched Metastases and Relationship with Overall Survival","volume":"36","author":"Yan","year":"2016","journal-title":"Anticancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/s41568-019-0213-x","article-title":"Controversies around epithelial-mesenchymal plasticity in cancer metastasis","volume":"19","author":"Williams","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1093\/annonc\/mdv297","article-title":"Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Dummer","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11864-019-0666-x","article-title":"Adjuvant Therapy for Melanoma","volume":"20","author":"Ito","year":"2019","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.clindermatol.2012.08.016","article-title":"Chemotherapy in the management of advanced cutaneous malignant melanoma","volume":"31","author":"Luke","year":"2013","journal-title":"Clin. Dermatol."},{"key":"ref_67","first-page":"488","article-title":"Treatment of metastatic melanoma: An overview","volume":"23","author":"Bhatia","year":"2009","journal-title":"Oncology"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Velho, T.R. (2012). Metastatic melanoma\u2014A review of current and future drugs. Drugs Context, 212242.","DOI":"10.7573\/dic.212242"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jmir.2019.05.001","article-title":"The pathogenesis and clinical management of cutaneous melanoma: An evidence-based review","volume":"50","author":"Burns","year":"2019","journal-title":"J. Med. Imaging Radiat. Sci."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.critrevonc.2013.01.003","article-title":"Targeting BRAF in melanoma: Biological and clinical challenges","volume":"87","author":"Voit","year":"2013","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1111\/ijd.12724","article-title":"Bench to bedside: Mechanistic principles of targeting the RAF kinase in melanoma","volume":"53","author":"Rajakulendran","year":"2014","journal-title":"Int. J. Dermatol."},{"key":"ref_76","first-page":"313","article-title":"Many ways to resistance: How melanoma cells evade targeted therapies","volume":"1871","author":"Kozar","year":"2019","journal-title":"BBA\u2014Rev. Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ccell.2014.11.018","article-title":"Tunable-combinatorial mechanisms of acquired Resistance limit the efficacy of BRAF\/MEK cotargeting but result in melanoma drug addiction","volume":"27","author":"Moriceau","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/onc.2017.391","article-title":"Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition","volume":"37","author":"Dietrich","year":"2018","journal-title":"Oncogene"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"17753","DOI":"10.18632\/oncotarget.3924","article-title":"miR-514a regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma","volume":"6","author":"Stark","year":"2015","journal-title":"Oncotarget"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1093\/annonc\/mdx176","article-title":"Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E\/K-mutant melanoma: Long-term survival and safety analysis of a phase 3 study","volume":"28","author":"Long","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): Updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","article-title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): A multicentre, open-label, randomised phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","article-title":"Targeted agents and immunotherapies: Optimizing outcomes in melanoma","volume":"14","author":"Luke","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","article-title":"Loss of PTEN promotes resistance to T cell-mediated immunotherapy","volume":"6","author":"Peng","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","article-title":"Tumor and microenvironment evolution during immunotherapy with nivolumab","volume":"171","author":"Riaz","year":"2017","journal-title":"Cell"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/(SICI)1097-0215(19960516)66:4<470::AID-IJC10>3.0.CO;2-C","article-title":"Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: Evidence for immunoselection of antigen-loss variants in vivo","volume":"66","author":"Jager","year":"1996","journal-title":"Int. J. Cancer"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.3389\/fonc.2021.672797","article-title":"Real Life Clinical Management and Survival in Advanced Cutaneous Melanoma: The Italian Clinical National Melanoma Registry Experience","volume":"11","author":"Crispo","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Savoia, P., Fava, P., Casoni, F., and Cremona, O. (2019). Targeting the ERK Signaling Pathway in Melanoma. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061483"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1021\/acs.molpharmaceut.0c00499","article-title":"pH-Sensitive Nanodrug Carriers for Codelivery of ERK Inhibitor and Gemcitabine Enhance the Inhibition of Tumor Growth in Pancreatic Cancer","volume":"18","author":"Ray","year":"2021","journal-title":"Mol. Pharm."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3389\/fonc.2015.00031","article-title":"Phenotype switching in melanoma: Implications for progression and therapy","volume":"5","author":"Li","year":"2015","journal-title":"Front. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1038\/jid.2014.194","article-title":"Imiquimod inhibits melanoma development by promoting pDC cytotoxic functions and impeding tumor vascularization","volume":"134","author":"Aspord","year":"2014","journal-title":"J. Invest. Dermatol."},{"key":"ref_97","first-page":"2","article-title":"Topical treatment of melanoma skin metastases with imiquimod: A review","volume":"21","author":"Sisti","year":"2014","journal-title":"Dermatol. Online J."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Sue, G.R., Hanlon, A., Lazova, R., and Narayan, D. (2014). Use of imiquimod for residual acral melanoma. BMJ Case Rep., bcr2014203826.","DOI":"10.1136\/bcr-2014-203826"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1515\/ntrev-2013-0013","article-title":"Nanotechnology for cancer treatment","volume":"3","author":"Gmeiner","year":"2014","journal-title":"Nanotechnol. Rev."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1007\/s00432-018-2726-1","article-title":"Melanoma treatment: From conventional to nanotechnology","volume":"144","author":"Mishra","year":"2018","journal-title":"J Cancer Res. Clin. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.apsb.2016.02.001","article-title":"Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: Current perspectives and future challenges","volume":"6","author":"Ha","year":"2016","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Arasi, M.B., Pedini, F., Valentini, S., Felli, N., and Felicetti, F. (2020). Advances in Natural or Synthetic Nanoparticles for Metastatic Melanoma Therapy and Diagnosis. Cancers, 12.","DOI":"10.3390\/cancers12102893"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1479-5876-3-10","article-title":"Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: Results of thefirst phase I clinical trial","volume":"3","author":"Escudier","year":"2005","journal-title":"J. Transl. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.7150\/thno.18752","article-title":"Exosomes Derived From Natural Killer Cells Exert Therapeutic Effect in Melanoma","volume":"7","author":"Zhu","year":"2017","journal-title":"Theranostics"},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Xiao, D., Ohlendorf, J., Chen, Y., Taylor, D.D., Rai, S.N., Waigel, S., Zacharias, W., Hao, H., and McMasters, K.M. (2012). Identifying mRNA, MicroRNA and Protein Profiles of Melanoma Exosomes. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0046874"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/pcmr.12380","article-title":"Proteome characterization of melanoma exosomes reveals a specific signature for metastatic cell lines","volume":"28","author":"Lazar","year":"2015","journal-title":"Pigment Cell Melanoma Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1710899","DOI":"10.1080\/20013078.2019.1710899","article-title":"Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients","volume":"9","author":"Cordonnier","year":"2020","journal-title":"J. Extracell Vesicles"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/bjc.2018.9","article-title":"PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC","volume":"118","author":"Marconcini","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Chill\u00e0, A., Margheri, F., Biagioni, A., Del Rosso, T., Fibbi, G., Del Rosso, M., and Laurenzana, A. (2020). Cell-Mediated Release of Nanoparticles as a Preferential Option for Future Treatment of Melanoma. Cancers, 12.","DOI":"10.3390\/cancers12071771"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3389\/fbioe.2020.00133","article-title":"Platelet-Like Gold Nanostars for Cancer Therapy: The Ability to Treat Cancer and Evade Immune Reactions","volume":"8","author":"Kim","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1039\/C4CC08831J","article-title":"Dual stimuli-responsive multi-drug delivery system for the individually controlled release of anti-cancer drugs","volume":"51","author":"Xiao","year":"2015","journal-title":"Chem. Commun."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.actbio.2015.01.026","article-title":"Nearinfrared light remote-controlled intracellular anti-cancer drug delivery using thermo\/pH sensitive nanovehicle","volume":"17","author":"Qin","year":"2015","journal-title":"Acta Biomater."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"173633","DOI":"10.1016\/j.ejphar.2020.173633","article-title":"Stimuli-responsive and cellular targeted nanoplatforms for multimodal therapy of skin cancer","volume":"890","author":"Singh","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jconrel.2014.12.030","article-title":"Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications","volume":"200","author":"Wicki","year":"2015","journal-title":"J. Control Release"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/10611860701231810","article-title":"Targeted nanoparticle-based drug delivery and diagnosis","volume":"15","author":"Emerich","year":"2007","journal-title":"J. Drug Target."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.drudis.2017.01.016","article-title":"Is the European regulatory framework sufficient to assure the safety of citizens using health products containing nanomaterials?","volume":"22","author":"Musazzi","year":"2017","journal-title":"Drug Discov. Today"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"16014","DOI":"10.1038\/natrevmats.2016.14","article-title":"Analysis of Nanoparticle Delivery to Tumours","volume":"1","author":"Wilhelm","year":"2016","journal-title":"Nat. Rev. Mater."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1517\/17425247.2012.673278","article-title":"Lipid nanoparticles: State of the art, new preparation methods and challenges in drug delivery","volume":"9","author":"Battaglia","year":"2012","journal-title":"Expert Opin Drug Deliv."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.2217\/nnm.13.157","article-title":"Choice of method for endotoxin detection depends on nanoformulation","volume":"9","author":"Dobrovolskaia","year":"2014","journal-title":"Nanomedicine"},{"key":"ref_120","first-page":"1","article-title":"Towards precision nanomedicine for cerebrovascular diseases with emphasis on Cerebral Cavernous Malformation (CCM)","volume":"23","author":"Perrelli","year":"2021","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/nbt.2786","article-title":"Clinical development success rates for investigational drugs","volume":"32","author":"Hay","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"ref_122","unstructured":"(2021, September 14). Database of Privately and Publicly Funded Clinical Studies, Available online: https:\/\/clinicaltrials.gov\/."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Ward, W.H., and Farma, J.M. (2017). Epidemiology of melanoma. Cutaneous Melanoma: Etiology and Therapy], Codon Publications.","DOI":"10.15586\/codon.cutaneousmelanoma.2017"},{"key":"ref_124","unstructured":"(2021, July 05). Fondazione AIOM (Associazione Italiana Oncologia Medica). Available online: https:\/\/www.fondazioneaiom.it\/quaderno-melanoma-cutaneo-2020\/."},{"key":"ref_125","unstructured":"(2021, July 05). QS quotidiano on line di informazione sanitaria. Available online: http:\/\/www.quotidianosanita.it\/scienza-e-farmaci\/articolo.php?articolo_id=89843."},{"key":"ref_126","unstructured":"(2021, July 05). L\u2019epidemiologia per la sanit\u00e0 pubblica-Istituto Superiore di Sanit\u00e0. Available online: https:\/\/www.epicentro.iss.it\/melanoma\/."},{"key":"ref_127","unstructured":"(2021, July 05). AIOM (Associazione Italiana di Oncologia Medica). Available online: https:\/\/www.aiom.it\/linee-guida-aiom-2020-melanoma\/."},{"key":"ref_128","unstructured":"(2021, September 15). International agency for research on cancer-World Health Organization. Available online: https:\/\/www-dep.iarc.fr\/whodb\/whodb.htm."},{"key":"ref_129","unstructured":"(2021, July 05). Intergruppo Melanoma Italiano (IMI). Available online: https:\/\/www.melanomaimi.it\/."},{"key":"ref_130","unstructured":"(2021, July 05). MiO, Melanoma Italia Onlus. Available online: https:\/\/www.melanomaitalia.org\/."},{"key":"ref_131","unstructured":"(2021, July 05). APaIM, Associazione Pazienti Italia Melanoma. Available online: https:\/\/apaim.it\/."},{"key":"ref_132","unstructured":"(2021, July 05). A.I.Ma.Me\u2013Associazione Italiana Malati di Melanoma e altri tumori della pelle. Available online: https:\/\/www.aimame.it\/."},{"key":"ref_133","unstructured":"(2021, July 20). Airi\/Nanotec IT - Nanotechnology in Italy. Available online: https:\/\/www.airi.it\/airi-nanotec-it\/."},{"key":"ref_134","unstructured":"(2021, July 20). Nanotechnology in Italy: Market Report. Available online: https:\/\/www.azonano.com\/article.aspx?ArticleID=3503."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/cplu.201300276","article-title":"\u201cClicking\u201d porphyrins to magnetic nanoparticles for photodynamic therapy","volume":"79","author":"Thandu","year":"2014","journal-title":"ChemPlusChem"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jphotobiol.2016.12.021","article-title":"Verteporfin based silica nanoparticle for in vitro selective inhibition of human highly invasive melanoma cell proliferation","volume":"167","author":"Rizzi","year":"2017","journal-title":"J. Photochem. Photobiol. B"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1039\/C5TB00234F","article-title":"Polymer nanoparticles with electrostatically loaded multicargo for combined cancer phototherapy","volume":"3","author":"Ballestri","year":"2015","journal-title":"J. Mater. Chem. B"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"3820","DOI":"10.1021\/bm400849n","article-title":"Supramolecular assemblies based on complexes of nonionic amphiphilic cyclodextrins and a meso-tetra(4-sulfonatophenyl)porphine tributyltin(iv) derivative: Potential nanotherapeutics against melanoma","volume":"14","author":"Mazzaglia","year":"2013","journal-title":"Biomacromolecules"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.1021\/nn500454n","article-title":"A smart platform for hyperthermia application in cancer treatment: Cobalt-doped ferrite nanoparticles mineralized in human ferritin cages","volume":"8","author":"Fantechi","year":"2014","journal-title":"ACS Nano"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.colsurfb.2018.04.031","article-title":"Repurposing itraconazole to the benefit of skin cancer treatment: A combined azole-DDAB nanoencapsulation strategy","volume":"167","author":"Carbone","year":"2018","journal-title":"Colloids Surf. B"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.colsurfb.2016.11.043","article-title":"Tocopheryl linolenate solid lipid nanoparticles for the encapsulation, protection, and release of the omega-3 polyunsaturated fatty acid: In vitro anti-melanoma activity evaluation","volume":"151","author":"Cassano","year":"2017","journal-title":"Colloids Surf. B"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejpb.2014.11.022","article-title":"Mesoporous silica as topical nanocarriers for quercetin: Characterization and in vitro studies","volume":"89","author":"Sapino","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2015.04.056","article-title":"Ultradeformable liposomes as multidrug carrier of resveratrol and 5-fluorouracil for their topical delivery","volume":"489","author":"Cosco","year":"2015","journal-title":"Int. J. Pharm."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Cristiano, M.C., Froiio, F., Spaccapelo, R., Mancuso, A., Nistic\u00f2, S.P., Udongo, B.P., Fresta, M., and Paolino, D. (2020). Sulforaphane-loaded ultradeformable vesicles as a potential natural nanomedicine for the treatment of skin cancer diseases. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12010006"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"12093","DOI":"10.1002\/chem.201801823","article-title":"Gold nanoparticles functionalized with RGD-semipeptides: A simple yet highly effective targeting system for avb3 integrins","volume":"24","author":"Maggi","year":"2018","journal-title":"Chem. Eur. J."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Fattore, L., Campani, V., Ruggiero, C.F., Salvati, V., Liguoro, D., Scotti, L., Botti, G., Ascierto, P.A., Mancini, R., and de Rosa, G. (2020). In vitro biophysical and biological characterization of lipid nanoparticles co-encapsulating oncosuppressors mir-199b-5p and mir-204-5p as potentiators of target therapy in metastatic melanoma. Int. Mol. Sci., 21.","DOI":"10.3390\/ijms21061930"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2147\/IJN.S96614","article-title":"Nanodiamonds coupled with 5,7-dimethoxycoumarin, a plant bioactive metabolite, interfere with the mitotic process in B16F10 cells altering the actin organization","volume":"3","author":"Gismondi","year":"2016","journal-title":"Int. J. Nanomed."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/mabi.201300114","article-title":"Hyaluronic acid nanohydrogels as a useful tool for BSAO immobilization in the treatment of melanoma cancer cells","volume":"13","author":"Montanari","year":"2013","journal-title":"Macromol. Biosci."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"111533","DOI":"10.1016\/j.jphotobiol.2019.111533","article-title":"Verteporfin-loaded mesoporous silica nanoparticles inhibit mouse melanoma proliferation in vitro and in vivo","volume":"197","author":"Clemente","year":"2019","journal-title":"J. Photochem. Photobiol. B"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1021\/acs.molpharmaceut.9b00047","article-title":"Tumor Targeting by Peptide-Decorated Gold Nanoparticles","volume":"16","author":"Albertini","year":"2019","journal-title":"Mol. Pharm."},{"key":"ref_151","first-page":"81","article-title":"Current State of Animal (Mouse) Modeling in Melanoma Research","volume":"8","author":"Kuzu","year":"2015","journal-title":"Cancer Growth Metastasis"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/01635581.2015.1037962","article-title":"Liquiritigenin potentiates the inhibitory effects of cisplatin on invasion and metastasis via downregulation MMP-2\/9 and PI3 K\/ AKT signaling pathway in B16F10 melanoma cells and mice model","volume":"67","author":"Shi","year":"2015","journal-title":"Nutr. Cancer"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.ejca.2003.11.028","article-title":"Of mice and men: Values and liabilities of the athymic nude mouse model in anticancer drug development","volume":"40","author":"Kelland","year":"2004","journal-title":"Eur. J. Cancer"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.ejca.2004.01.003","article-title":"Integrating pharmacology and in vivo cancer mod els in preclinical and clinical drug development","volume":"40","author":"Peterson","year":"2004","journal-title":"Eur. J. Cancer"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1038\/jid.2015.198","article-title":"Combined inhibition of MEK and Plk1 has synergistic anti-tumor activity in NRAS mutant melanoma","volume":"135","author":"Posch","year":"2015","journal-title":"J. Invest. Dermatol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1158\/1535-7163.MCT-14-0832","article-title":"The novel ATP-competitive MEK\/aurora kinase inhibitor BI-847325 overcomes acquired BRAF inhibitor resistance through sup pression of Mcl-1 and MEK expression","volume":"14","author":"Phadke","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1158\/0008-5472.CAN-10-2889","article-title":"eEF-2 k nase dictates cross-talk between autophagy and apoptosis induced by Akt inhibition, thereby modulating cyto toxicity of novel Akt inhibitor MK-2206","volume":"71","author":"Cheng","year":"2011","journal-title":"Cancer Res."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1158\/0008-5472.CAN-07-5867","article-title":"Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development","volume":"68","author":"Cheung","year":"2008","journal-title":"Cancer Res."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"E8","DOI":"10.1111\/pcmr.12099","article-title":"Meeting report: The future of preclinical mouse models in melanoma treatment is now","volume":"26","author":"Merlino","year":"2013","journal-title":"Pigment. Cell Melanoma Res."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nrclinonc.2012.61","article-title":"Patient-derived tumour xenografts as models for oncology drug development","volume":"9","author":"Tentler","year":"2012","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1158\/1078-0432.CCR-10-1382","article-title":"Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts","volume":"17","author":"Kortmann","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2013.10.010","article-title":"One mouse, one patient paradigm: New avatars of personalized cancer therapy","volume":"344","author":"Malaney","year":"2014","journal-title":"Cancer Lett."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S1471-4906(01)01943-3","article-title":"Human-SCID mouse chimeric models for the evaluation of anti-cancer therapies","volume":"22","author":"Bankert","year":"2001","journal-title":"Trends Immunol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/ng1586","article-title":"Use of human tissue to assess the oncogenic activity of melanoma-associated mutations","volume":"37","author":"Chudnovsky","year":"2005","journal-title":"Nat. Genet."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1600-0625.2009.00986.x","article-title":"Mouse models for melanoma: A personal perspective","volume":"19","author":"Becker","year":"2010","journal-title":"Exp. Dermatol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1038\/jid.2008.177","article-title":"From UVs to metastases: Modeling mela noma initiation and progression in the mouse","volume":"128","author":"Zaidi","year":"2008","journal-title":"J. Invest. Dermatol."},{"key":"ref_167","first-page":"5157","article-title":"c-Met autocrine activation induces devel opment of malignant melanoma and acquisition of the metastatic phenotype","volume":"58","author":"Otsuka","year":"1998","journal-title":"Cancer Res."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1073\/pnas.94.2.701","article-title":"Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor\/ scatter factor","volume":"94","author":"Takayama","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1087-0024.2005.200409.x","article-title":"Animal models of melanoma","volume":"10","author":"Ha","year":"2005","journal-title":"J. Invest. Dermatol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/35095108","article-title":"Neonatal sunburn and melanoma in mice","volume":"413","author":"Noonan","year":"2001","journal-title":"Nature"},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Teicher, B.A. (2011). Tumor Models in Cancer Research, Humana Press.","DOI":"10.1007\/978-1-60761-968-0"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"153","DOI":"10.5732\/cjc.011.10007","article-title":"Animal models of melanoma: A somatic cell gene delivery mouse model allows rapid evaluationof genes implicatedin human melanoma","volume":"30","author":"McKinney","year":"2011","journal-title":"Chin. J. Cancer"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1254\/jjp.86.302","article-title":"Mechanism of 7,12 dimethylbenz [a]anthracene-induced immunotoxicity: Role of metabolic activation at the target organ","volume":"86","author":"Miyata","year":"2001","journal-title":"Jpn. J. Pharmacol."},{"key":"ref_174","first-page":"1","article-title":"Protein kinase c as the receptor for the phorbol ester tumor promoters: Sixth rhoads memorial award lecture","volume":"48","author":"Blumberg","year":"1988","journal-title":"Cancer Res."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/311480a0","article-title":"Protein kinase c phosphorylation of the egf receptor at a thre onine residue close to thecytoplasmic face of the plasma membrane","volume":"311","author":"Hunter","year":"1984","journal-title":"Nature"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2353\/ajpath.2006.060017","article-title":"Rapid growth of invasive metastatic melanoma in carcinogen tre ated hepatocyte growth factor\/scatter factor transgenic mice carrying an oncogenic cdk4 mutation","volume":"169","author":"Tormo","year":"2006","journal-title":"Am. J. Pathol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.1158\/0008-5472.CAN-08-0889","article-title":"Pten deficiency in melanocytes results in resistance to hair graying and susceptibility to carcinogen-induced melanomagenesis","volume":"68","author":"Hamada","year":"2008","journal-title":"Cancer Res."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.taap.2003.09.029","article-title":"Topical application of dimethylbenz [a]anthracene results in the generation of multiple melanocytic nevi in c3h\/hen mice","volume":"195","author":"Elmets","year":"2004","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jconrel.2012.08.027","article-title":"Subcellular trafficking and trans fection efficacy of polyethylenimine-polyethylene glycol polyplex nanoparticles with a ligand to melanocortin receptor-1","volume":"163","author":"Durymanov","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_180","first-page":"467","article-title":"Modular nanotransporters: A multipurpose in vivo working platform for targeted drug delivery","volume":"7","author":"Slastnikova","year":"2012","journal-title":"Int. J. Nanomed."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/ng.3361","article-title":"Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas","volume":"47","author":"Krauthammer","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1200\/JCO.1998.16.2.670","article-title":"Molecular genetics of familial cutaneous melanoma","volume":"16","author":"Haluska","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/ng0994-15","article-title":"Germline p16 mutations in familial melanoma","volume":"8","author":"Hussussian","year":"1994","journal-title":"Nat. Genet."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/ng0994-22","article-title":"Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus","volume":"8","author":"Kamb","year":"1994","journal-title":"Nat. Genet."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1073\/pnas.88.1.164","article-title":"Malignant melanoma in trans genic mice","volume":"88","author":"Bradl","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1006\/scbi.2000.0342","article-title":"Cellular transformation by SV40 large T antigen: Interaction with host proteins","volume":"11","author":"Ali","year":"2001","journal-title":"Semin. Cancer Biol."},{"key":"ref_187","first-page":"4569","article-title":"Ultraviolet radiation-induced malig nant skin melanoma in melanoma-susceptible transgenic mice","volume":"54","author":"Silvers","year":"1994","journal-title":"Cancer Res."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0092-8674(00)81079-X","article-title":"Role of the INK4a locus in tumor suppression and cell mortality","volume":"85","author":"Serrano","year":"1996","journal-title":"Cell"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/35092584","article-title":"Loss of p16Ink4a con fers susceptibility to metastatic melanoma in mice","volume":"413","author":"Krimpenfort","year":"2001","journal-title":"Nature"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/35092592","article-title":"Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis","volume":"413","author":"Sharpless","year":"2001","journal-title":"Nature"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"5649","DOI":"10.1158\/0008-5472.CAN-06-3806","article-title":"Loss of xeroderma pigmentosum C (Xpc) enhances melanoma photocarcinogenesis in Ink4a-Arf-deficient mice","volume":"67","author":"Yang","year":"2007","journal-title":"Cancer Res."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1093\/carcin\/20.9.1747","article-title":"Induction of melanoma in TPras transgenic mice","volume":"20","author":"Gause","year":"1999","journal-title":"Carcinogenesis"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1101\/gad.11.21.2822","article-title":"Cooperative effects of INK4a and ras in melanoma susceptibility in vivo","volume":"11","author":"Chin","year":"1997","journal-title":"Genes Dev."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1158\/0008-5472.CAN-04-2970","article-title":"Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background","volume":"65","author":"Ackermann","year":"2005","journal-title":"Cancer Res."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"5809","DOI":"10.1038\/onc.2010.314","article-title":"Somatic p16(INK4a) loss accelerates melanomagenesis","volume":"29","author":"Monahan","year":"2010","journal-title":"Oncogene"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/j.0022-202X.2005.23917.x","article-title":"Neonatal ultraviolet radiation exposure is critical for malignant melanoma induction in pigmented Tpras transgenic mice","volume":"125","author":"Hacker","year":"2005","journal-title":"J. Investig. Dermatol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/gene.20182","article-title":"Spatiotemporal gene control by the Cre-ERT2 system in melanocytes","volume":"44","author":"Yajima","year":"2006","journal-title":"Genesis"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.ajpath.2012.06.002","article-title":"Targeting BRAFV600E in an inducible murine model of melanoma","volume":"181","author":"Hooijkaas","year":"2012","journal-title":"Am. J. Pathol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/nprot.2012.060","article-title":"Production of avian retroviruses and tissue-specific somatic retroviral gene transfer in vivo using the RCAS\/TVA system","volume":"7","author":"Seidler","year":"2012","journal-title":"Nat. Protoc."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1755-148X.2010.00717.x","article-title":"Tar geted delivery of NRASQ61R and Cre-recombinase to post-natal melanocytes induces melanoma in Ink4a\/Arflox\/lox mice","volume":"23","author":"Robinson","year":"2010","journal-title":"Pigment. Cell Melanoma Res."},{"key":"ref_201","first-page":"1491","article-title":"Establishment and characterization of a malignant melanocytic tumor cell line expressing the ret oncogene","volume":"7","author":"Taniguchi","year":"1992","journal-title":"Oncogene"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/ng1148","article-title":"Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia","volume":"34","author":"Pollock","year":"2003","journal-title":"Nat. Genet."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/sj.ejhg.5201887","article-title":"Genetic analysis of the GRM1 gene in human melanoma susceptibility","volume":"15","author":"Ortiz","year":"2007","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.exer.2014.07.009","article-title":"Tg(Grm1) transgenic mice: A murine model that mimics spontaneous uveal mel anoma in humans?","volume":"127","author":"Schiffner","year":"2014","journal-title":"Exp. Eye Res."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ccr.2014.04.016","article-title":"Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry","volume":"25","author":"Feng","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_206","doi-asserted-by":"crossref","unstructured":"Onken, M.D., Worley, L.A., Long, M.D., Duan, S., Council, M.L., Bowcock, A.M., and Harbour, J.W. (2008). Oncogenic mutations in GNAQ occur early in uveal melanoma. Investig. Ophthalmol. Vis. Sci., 49.","DOI":"10.1167\/iovs.08-2145"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1755-148X.2010.00693.x","article-title":"Genetic and environmental melanoma models in fish","volume":"23","author":"Patton","year":"2010","journal-title":"Pigment. Cell Melanoma Res."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1007\/s1012601-0004-7","article-title":"Genetic analysis of susceptibility to spontaneous and UV-induced carcinogenesis in Xiphophorus hybrid fish","volume":"3","author":"Nairn","year":"2001","journal-title":"Mar. Biotechnol."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1007\/s10126001-0025-2","article-title":"Genetic analysis of neoplasia induced by N-nitroso-N-methylurea in Xiphophorus hybrid fish","volume":"3","author":"Kazianis","year":"2001","journal-title":"Mar. Biotechnol."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/ilar.42.4.299","article-title":"Xiphophorus interspecies hybrids as genetic models of induced neoplasia","volume":"42","author":"Walter","year":"2001","journal-title":"ILAR J."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1089\/zeb.2008.9992","article-title":"From Xiphophorus to melanoma\u2014A tribute to Steven Kazianis (1966\u20132008)","volume":"5","author":"Haass","year":"2008","journal-title":"Zebrafish"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.cub.2005.01.031","article-title":"BRAF mutation are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma","volume":"15","author":"Patton","year":"2005","journal-title":"Curr. Biol."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/jid.2009.213","article-title":"A mutated EGFR is sufficient to induce malignant melanoma with genetic background-dependent histopathologies","volume":"130","author":"Schartl","year":"2010","journal-title":"J. Investig. Dermatol."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/35103567","article-title":"The art and design of genetic screens: Zebrafish","volume":"2","author":"Patton","year":"2001","journal-title":"Nat. Rev. Genet."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nmeth0707-548","article-title":"Imaging neoplasia in zebrafish","volume":"4","author":"Spitsbergen","year":"2007","journal-title":"Nat. Methods"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/nrc1126","article-title":"Cancer genetics and drug discovery in the zebrafish","volume":"3","author":"Stern","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0065-230X(00)79004-X","article-title":"Animal models of melanoma: Recent advances and future prospects","volume":"79","author":"Bardeesy","year":"2000","journal-title":"Adv. Cancer Res."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/00008390-199712000-00005","article-title":"Regression by differentiation in the Sinclair swine model of cutaneous melanoma","volume":"7","author":"Greene","year":"1997","journal-title":"Melanoma Res."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/1523-1747.ep12676714","article-title":"Melanoma in Sinclair swine: A new animal model","volume":"62","author":"Millikan","year":"1974","journal-title":"J. Investig. Dermatol."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1034\/j.1600-0749.2000.130109.x","article-title":"The study of cutaneous melanomas in Camargue-type gray-skinned horses (2): Epidemiological survey","volume":"13","author":"Fleury","year":"2000","journal-title":"Pigment. Cell Res."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1034\/j.1600-0749.2000.130108.x","article-title":"The study of cutaneous melanomas in Camargue-type gray-skinned horses (1): Clinical-pathological characterization","volume":"13","author":"Fleury","year":"2000","journal-title":"Pigment. Cell Res."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/ng.185","article-title":"A cis-acting regulatory mutation causes premature hair graying and susceptibility to melanoma in the horse","volume":"40","author":"Golovko","year":"2008","journal-title":"Nat. Genet."},{"key":"ref_223","first-page":"d1531","article-title":"Animal models of ultraviolet radiation (UVR)-induced cutaneous melanoma","volume":"7","author":"Ley","year":"2002","journal-title":"Front. Biosci"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00008390-200508000-00001","article-title":"Human SK-Mel 28 melanoma cells resume neural crest cell migration after transplantation into the chick embryo","volume":"15","author":"Schriek","year":"2005","journal-title":"Melanoma Res."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/CMR.0b013e3280114f49","article-title":"Non-malignant migration of B16 mouse melanoma cells in the neural crest and invasive growth in the eye cup of the chick embryo","volume":"17","author":"Oppitz","year":"2007","journal-title":"Melanoma Res."},{"key":"ref_226","first-page":"1367","article-title":"Neural crest cell migration of mouse B16-F1 melanoma cells transplanted into the chick embryo is inhibited by the BMP-antagonist noggin","volume":"31","author":"Busch","year":"2007","journal-title":"Int. J. Oncol."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1002\/ijc.23139","article-title":"Noggin blocks invasive growth of murine B16-F1 melanoma cells in the optic cup of the chick embryo","volume":"122","author":"Busch","year":"2008","journal-title":"Int. J. Cancer"},{"key":"ref_228","doi-asserted-by":"crossref","unstructured":"Busch, C., Krochmann, J., and Drews, U. (2013). The chick embryo as an experimental system for melanoma cell invasion. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0053970"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1755-148X.2011.00914.x","article-title":"Melanoma cells in distinct growth phases retain specific invasive qualities during brain metastasis in vivo","volume":"25","author":"Krochmann","year":"2012","journal-title":"Pigment. Cell Melanoma Res."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3390\/healthcare2010027","article-title":"Modeling Melanoma In Vitro and In Vivo","volume":"2","author":"Beaumont","year":"2013","journal-title":"Healthcare"},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1039\/C9BM01766F","article-title":"Leukocyte-mimicking nanovesicles for effective doxorubicin delivery to treat breast cancer and melanoma","volume":"8","author":"Molinaro","year":"2020","journal-title":"Biomater. Sci."},{"key":"ref_232","doi-asserted-by":"crossref","unstructured":"Clemente, N., Argenziano, M., Gigliotti, C.L., Ferrara, B., Boggio, E., Chiocchetti, A., Caldera, F., Trotta, F., Benetti, E., and Annaratone, L. (2019). Paclitaxel-Loaded Nanosponges Inhibit Growth and Angiogenesis in Melanoma Cell Models. Front. Pharmacol., 10.","DOI":"10.3389\/fphar.2019.00776"},{"key":"ref_233","doi-asserted-by":"crossref","unstructured":"Clemente, N., Ferrara, B., Gigliotti, C.L., Boggio, E., Capucchio, M.T., Biasibetti, E., Schiffer, D., Mellai, M., Annovazzi, L., and Cangemi, L. (2018). Solid Lipid Nanoparticles Carrying Temozolomide for Melanoma Treatment Preliminary In Vitro and In Vivo Studies.. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19020255"},{"key":"ref_234","doi-asserted-by":"crossref","unstructured":"Dianzani, C., Monge, C., Miglio, G., Serpe, L., Martina, K., Cangemi, L., Ferraris, C., Mioletti, S., Osella, S., and Gigliotti, C.L. (2020). Nanoemulsions as Delivery Systems for Poly-Chemotherapy Aiming at Melanoma Treatment. Cancers, 12.","DOI":"10.3390\/cancers12051198"},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"13015","DOI":"10.1021\/acsomega.9b00489","article-title":"Codelivery of mRNA with \u03b1-Galactosylceramide Using a New Lipopolyplex Formulation Induces a Strong Antitumor Response upon Intravenous Administration","volume":"4","author":"Guevara","year":"2019","journal-title":"ACS Omega"},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jconrel.2015.12.037","article-title":"A novel liposomal Clodronate depletes tumor-associated macrophages in primary and metastatic melanoma: Anti-angiogenic and anti-tumor effects","volume":"223","author":"Piaggio","year":"2016","journal-title":"J. Control. Release"},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jconrel.2020.01.030","article-title":"Immunotherapy of experimental melanoma with ICOS-Fc loaded in biocompatible and biodegradable nanoparticles","volume":"320","author":"Clemente","year":"2020","journal-title":"J. Control. Release"},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/s41565-019-0512-0","article-title":"Immunization with mannosylated nanovaccines and inhibition of the immune-suppressing microenvironment sensitizes melanoma to immune checkpoint modulators","volume":"14","author":"Conniot","year":"2019","journal-title":"Nat. Nanotechnol."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1016\/j.ejca.2010.02.037","article-title":"The in vivo efficacy of phthalocyanine-nanoparticle conjugates for the photodynamic therapy of amelanotic melanoma","volume":"46","author":"Camerin","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1039\/c5pp00463b","article-title":"Delivery of a hydrophobic phthalocyanine photosensitizer using PEGylated gold nanoparticle conjugates for the in vivo photodynamic therapy of amelanotic melanoma","volume":"15","author":"Camerin","year":"2016","journal-title":"Photochem. Photobiol. Sci."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s10637-015-0291-x","article-title":"Fibrin gels loaded with cisplatin and cisplatin-hyaluronate complexes tested in a subcutaneous human melanoma model","volume":"33","author":"Viale","year":"2015","journal-title":"Investig. New Drugs"},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"12278","DOI":"10.1039\/c3nr04268e","article-title":"Antibody\u2013drug conjugates: Targeting melanoma with cisplatin encapsulated in protein-cage nanoparticles based on human ferritin","volume":"5","author":"Falvo","year":"2013","journal-title":"Nanoscale"},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1158\/1078-0432.CCR-15-2170","article-title":"TNF-Related Apoptosis-Inducing Ligand (TRAIL)-Armed Exosomes Deliver Proapoptotic Signals to Tumor Site","volume":"22","author":"Rivoltini","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jconrel.2012.12.026","article-title":"Biodegradable core-shell nanoassemblies for the delivery of docetaxel and Zn(II)-phthalocyanine inspired by combination therapy for cancer","volume":"167","author":"Conte","year":"2013","journal-title":"J. Control. Release"},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"2001175","DOI":"10.1002\/advs.202001175","article-title":"Enhanced Antitumoral Activity and Photoacoustic Imaging Properties of AuNP-Enriched Endothelial Colony Forming Cells on Melanoma","volume":"8","author":"Armanetti","year":"2021","journal-title":"Adv. Sci."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"102902","DOI":"10.1016\/j.ebiom.2020.102902","article-title":"Real-time imaging of polymersome nanoparticles in zebrafish embryos engrafted with melanoma cancer cells: Localization, toxicity and treatment analysis","volume":"58","author":"Kocere","year":"2020","journal-title":"EBioMedicine"},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2016.12.024","article-title":"A catechin nanoformulation inhibits WM266 melanoma cell proliferation, migration and associated neo-angiogenesis","volume":"114","author":"Battaglini","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1038\/s41467-020-15546-9","article-title":"Pre-clinical modeling of cutaneous melanoma","volume":"11","author":"Rebecca","year":"2020","journal-title":"Nat. Commun"},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/pcmr.12104","article-title":"Ret transgenic mouse model of spontaneous skin melanoma: Focus on regulatory T cells","volume":"26","author":"Umansky","year":"2013","journal-title":"Pigment. Cell Melanoma Res."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.celrep.2019.07.033","article-title":"Inflammatory Activation of Astrocytes Facilitates Melanoma Brain Tropism via the CXCL10-CXCR3 Signaling Axis","volume":"28","author":"Doron","year":"2019","journal-title":"Cell Rep."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/pcmr.12220","article-title":"Multiple murine BRaf(V600E) melanoma cell lines with sensitivity to PLX4032","volume":"27","author":"Jenkins","year":"2014","journal-title":"Pigment. Cell Melanoma Res."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"2000028","DOI":"10.1002\/adtp.202000028","article-title":"Rational Design of Polyglutamic Acid Delivering an Optimized Combination of Drugs Targeting Mutated BRAF and MEK in Melanoma","volume":"3","author":"Pisarevsky","year":"2020","journal-title":"Adv. Ther."},{"key":"ref_253","doi-asserted-by":"crossref","unstructured":"Bozzer, S., Bo, M.D., Toffoli, G., Macor, P., and Capolla, S. (2021). Nanoparticles-Based Oligonucleotides Delivery in Cancer: Role of Zebrafish as Animal Model. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13081106"},{"key":"ref_254","doi-asserted-by":"crossref","unstructured":"Edgar, J.R. (2016). Q&A: What are exosomes, exactly?. BMC Biol., 14.","DOI":"10.1186\/s12915-016-0268-z"},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.bbagen.2017.01.015","article-title":"Formulation of liposomes functionalized with Lotus lectin and effective in targeting highly proliferative cells","volume":"1861","author":"Capone","year":"2017","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"335706","DOI":"10.1088\/0957-4484\/25\/33\/335706","article-title":"A biodistribution study of PEGylated PCL-based nanoparticles in C57BL\/6 mice bearing B16\/F10 melanoma","volume":"25","author":"Lupi","year":"2014","journal-title":"Nanotechnology"},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"4166","DOI":"10.4049\/jimmunol.1600833","article-title":"4PD Functionalized Dendrimers: A Flexible Tool for In Vivo Gene Silencing of Tumor-Educated Myeloid Cells","volume":"198","author":"Zilio","year":"2017","journal-title":"J. Immunol."},{"key":"ref_258","doi-asserted-by":"crossref","unstructured":"Yl\u00f6sm\u00e4ki, L., Polini, B., Carpi, S., Martins, B., Smertina, E., Feola, S., Fusciello, M., Peltonen, K., Nieri, P., and Yl\u00f6sm\u00e4ki, E. (2019). Harnessing therapeutic viruses as a delivery vehicle for RNA-based therapy. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0224072"},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.nano.2016.08.022","article-title":"Oil\/water nano-emulsion loaded with cobalt ferrite oxide nanocubes for photo-acoustic and magnetic resonance dual imaging in cancer: In vitro and preclinical studies","volume":"13","author":"Vecchione","year":"2017","journal-title":"Nanomed.: Nanotechnol. Biol. Med."},{"key":"ref_260","doi-asserted-by":"crossref","unstructured":"Argenziano, M., Grattarola, M., Cucci, M.A., and Pizzimenti, S. (2021, January 14\u201323). Cavalli Harnessing Nrf2-targeting siRNA loaded nanobubbles to overcome melanoma resistance. Proceedings of the Congresso SCI 2021, Virtual edition.","DOI":"10.3390\/pharmaceutics14020341"},{"key":"ref_261","unstructured":"Dianzani, U., Gigliotti, C.L., and Boggio, E. (2016). Ligands of B7h rReceptor in the Treatment of Osteopenia and Osteoporosis. International Application. (No. PCT\/IB2016\/052903), U.S. Patent."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"4921","DOI":"10.4049\/jimmunol.1300587","article-title":"B7h Triggering Inhibits the Migration of Tumor Cell Lines","volume":"192","author":"Dianzani","year":"2014","journal-title":"J. Immunol."},{"key":"ref_263","unstructured":"Dianzani, U., Gigliotti, C.L., Boggio, E., Clemente, N., Chiocchetti, A., Trotta, F., Cavalli, R., and Dianzani, C. (2019). Anti-tumor Therapeutic Agents Based on b7h Receptor Ligand. International Application. (No PCT\/IB2019\/050154), U.S. Patent."},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"17455","DOI":"10.1039\/C5CC06032J","article-title":"GdDOTAGA(C18)2: An efficient amphiphilic Gd(iii) chelate for the preparation of self-assembled high relaxivity MRI nanoprobes","volume":"51","author":"Filippi","year":"2015","journal-title":"Chem. Comm."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/CMR.0000000000000350","article-title":"BRAF inhibitor discontinuation and rechallenge in advanced melanoma patients with a complete initial treatment response","volume":"27","author":"Desvignes","year":"2017","journal-title":"Melanoma Res."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: Epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrc.2016.108","article-title":"Cancer nanomedicine: Progress, challenges and opportunities","volume":"17","author":"Shi","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"601626","DOI":"10.3389\/fphar.2021.601626","article-title":"Biodegradable Polymeric Nanoparticles for Drug Delivery to Solid Tumors","volume":"12","author":"Gagliardi","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/anie.200502113","article-title":"Polymer therapeutics: Concepts and applications","volume":"45","author":"Haag","year":"2006","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"661214","DOI":"10.3389\/fbioe.2021.661214","article-title":"Recent Progress in Nanomedicine for Melanoma Theranostics With Emphasis on Combination Therapy","volume":"9","author":"Guan","year":"2021","journal-title":"Front. Bioeng. Biotechnol."},{"key":"ref_271","doi-asserted-by":"crossref","unstructured":"Begines, B., Ortiz, T., P\u00e9rez-Aranda, M., Mart\u00ednez, G., Merinero, M., Arg\u00fcelles-Arias, F., and Alcudia, A. (2020). Polymeric Nanoparticles for Drug Delivery: Recent Developments and Future Prospects. Nanomaterials, 10.","DOI":"10.3390\/nano10071403"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/13\/10\/1617\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:09:27Z","timestamp":1760166567000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/13\/10\/1617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,4]]},"references-count":271,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["pharmaceutics13101617"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics13101617","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,4]]}}}